secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2026-07-28T01:01:17+00:00
Accession:  0001714899-26-000086
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics sells rare pediatric disease PRV for $195M
--------------------------------------------------------------

- Gross proceeds of $195M from sale of PRV to a large pharmaceutical company.
- PRV received from FDA approval of AVLAYA (tividenofusp alfa) for Hunter syndrome in March 2026.
- Sale closed on July 27, 2026, per asset purchase agreement dated June 12, 2026.
- Proceeds provide significant cash infusion; no other terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/0001714899-26-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm
  HTML page:      https://secwatch.observer/filing/0001714899-26-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer